Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Incyte Corp

NASDAQ: INCY · Industrial Applications and Services · 6 alerts · CIK 879169

Share price
$120.27Close, Nov 16
Market cap
$24.5B
Shares outstanding
203.83MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Services-Commercial Physical & Biological ResearchSIC 8731

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Incyte Corp filings on SEC EDGAR ↗

4:04 PM ET 10-Q
Financial Results

Incyte Q3 2026 Results: Net Loss of $785M

Incyte Corporation reported total revenues of $4.5 billion for the nine months ended September 30, 2026, a significant increase from $3.6 billion in the prior year. However, the company recorded a net loss of $784.8 million for the third quarter of 2026, primarily driven by a substantial increase in research and development expenses to $1.79 billion.

Key figure
Net loss $785M
7:04 AM ET 8-K
Financial Results

Incyte Financial Results

Incyte reported third quarter 2026 total revenue of $1.56 billion, a 14% year-over-year increase driven by strong sales of Jakafi ($827M) and Opzelura ($255M). The company raised its full-year 2026 financial guidance for total net sales and key product portfolios. Results were impacted by a one-time $1.23 billion R&D expense related to the acquisition of Vega Therapeutics.

Term
Q3 2026

“Our third quarter was marked by strong commercial performance, meaningful pipeline progress and important regulatory achievements. Net sales growth was strong in both the U.S. and internationally, creating a durable core business beyond Jakafi.”

Bill Meury, Chief Executive Officer, Incyte

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.